Nancy Stagliano, CEO of Neuron23, is fascinated by how the brain works. “Of all parts of the body, to me it is the most interesting and the most complex,” she explains. “I think the brain is the final frontier.” Nancy has always been driven by her love of science and medicine, receiving a PhD in neuroscience, and degrees in both biomedical and electrical engineering, followed by a postdoc at Harvard Medical School. She holds numerous patents and published works in respected journals. During her career, Nancy has been CEO of three successful companies—True North Therapeutics, iPierian, and CytomX Therapeutics. Nancy is passionate about building high performing teams dedicated to finding new therapies that make a difference for patients. “Success to me is defined by getting a therapeutic to patients,” she says. “I think my crowning career achievement to-date is the work I did with True North.” True North’s drug, Enjaymo (Sutimlimab), now in the hands of Sanofi, recently won FDA approval for the treatment of cold agglutinin disease, a rare condition in which the body’s immune system mistakenly attacks and destroys its own red blood cells. As the CEO and chair at Neuron23, Nancy takes a hands-on approach to building the company, following the science, and mentoring the team. In addition to her commitment to Neuron23, Nancy serves as chair of the board of a number of biotechnology companies, including Star Therapeutics, Electra Therapeutics and Latigo Biosciences. Nancy is active in philanthropy and is a board member of the not-for-profit organization PanCAN, having lost her mother and uncle to pancreatic cancer. Nancy was previously involved as an advisor to Westlake Village BioPartners and New Leaf Venture Partners.